Table 5.
COVID-19’s effect on gynecologic patients
| Respondents |
||
|---|---|---|
| Question | % | No. |
| Positive COVID-19 test during treatment | ||
| Yes | 65.1 | 28 |
| No | 34.9 | 15 |
| Active treatment of patients with COVID-19 | ||
| No | 39.0 | 16 |
| Yes, EBRT only | 19.5 | 8 |
| Yes, brachytherapy only | 7.3 | 3 |
| Yes, EBRT and brachytherapy | 34.1 | 14 |
| Pause or delay in treatment due to positive COVID-19 test | ||
| Yes | 45.2 | 19 |
| No | 54.8 | 23 |
| Died due to COVID-19 or related causes | ||
| Yes | 16.3 | 7 |
| No | 83.7 | 36 |
| Total treatment time >8 wk for cervical cancer | ||
| Yes, <25% of patients | 32.6 | 14 |
| Yes, 25%-50% of patients | 0.0 | 0 |
| Yes, >50% of patients | 0.0 | 0 |
| No | 67.4 | 29 |
| Required COVID-19 test before treatment | ||
| Yes | 65.1 | 28 |
| No | 34.9 | 15 |
| When is COVID-19 test required? | ||
| Before EBRT | 14.3 | 4 |
| Before brachytherapy | 25.0 | 7 |
| Before EBRT and brachytherapy | 35.7 | 10 |
| Before anesthesia only | 25.0 | 7 |
| Delayed by testing | ||
| <25% of patients | 100.0 | 28 |
| 25%-50% of patients | 0.0 | 0 |
| >50% of patients | 0.0 | 0 |
| Did patients self-delay due to COVID-19 risk? | ||
| Yes | 55.8 | 24 |
| No | 44.2 | 19 |
| Self-delay | ||
| <25% of patients | 91.7 | 22 |
| 25%-50% of patients | 8.3 | 2 |
| >50% of patients | 0.0 | 0 |
Abbreviation: EBRT = external beam radiation therapy.